UIH(688271) 浙商证券·2025-05-13 10:45Investment Rating - The investment rating for the company is "Accumulate" [6] Core Views - The company is expected to see a recovery in demand and significant profit growth in 2025, driven by the resumption of hospital bidding and the introduction of high-end products [1][2] - The company's revenue for 2024 is projected to be 10.3 billion yuan, a decrease of 9.7% year-on-year, while the net profit attributable to the parent company is expected to be 1.262 billion yuan, down 36.1% year-on-year [1] - The first quarter of 2025 shows positive revenue growth of 5.4% year-on-year, with net profit attributable to the parent company increasing by 1.9% [1][2] Summary by Sections Revenue and Profitability - In Q4 2024, the company reported revenue of 3.346 billion yuan, a decline of 15.9% year-on-year but a 106% increase quarter-on-quarter [1] - The company’s revenue for Q1 2025 is 2.478 billion yuan, reflecting a year-on-year growth of 5.4% [1] - The net profit for Q1 2025 is 370 million yuan, up 1.9% year-on-year, while the non-recurring net profit is 379 million yuan, showing a significant increase of 26.1% [1] Market Position and Product Development - The company’s market share increased by over 3 percentage points in 2024, particularly in high-end products, which saw a nearly 5 percentage point increase in market share [2] - New product launches in 2024 include the uLinacHalosTx precision radiotherapy system and the uMRMax next-generation 3.0T MRI, which are expected to enhance the company's competitive position [2] International Expansion - The company achieved overseas revenue of 2.22 billion yuan in 2024, a year-on-year increase of 33.81%, with overseas revenue accounting for 21.55% of total revenue [3] - The company has received CE certification for 46 products and FDA approval for 49 products, enhancing its international market presence [3] Profitability Forecast - The gross profit margin for 2024 is expected to be 48.54%, with a slight increase anticipated in 2025 [4] - The net profit margin for 2024 is projected at 12.06%, with expectations for improvement in 2025 as the company benefits from economies of scale [4] Financial Projections - Revenue projections for 2025, 2026, and 2027 are 12.251 billion yuan, 14.478 billion yuan, and 17.325 billion yuan, respectively, with year-on-year growth rates of 18.94%, 18.18%, and 19.67% [5] - The net profit attributable to the parent company is expected to reach 1.799 billion yuan in 2025, reflecting a year-on-year growth of 42.59% [5]